Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Vildagliptin launched by Novartis for dual therapy in type 2 diabetes

Patients with type 2 diabetes could be suitable for treatment with a new medicine, vildagliptin, available in the UK this week. Novartis has launched the drug both as a single ingredient tablet (Galvus) and as a combination product with metformin (Eucreas).

Galvus has received a licence for dual therapy in combination with:

• Metformin, for patients with insufficient glycaemic control despite the maximum tolerated dose of monotherapy with metformin

• A sulphonylurea, for patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance

• A thiazolidinedione, for patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate

Vildagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of antidiabetic drugs. As a potent and selective inhibitor of DPP-4, vildagliptin causes rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

According to Novartis, increasing these incretin hormones enhances the sensitivity of beta cells to glucose resulting in improved glucose-dependent insulin secretion. By raising GLP-1 levels the drug also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.

Citation: The Pharmaceutical Journal URI: 10006309

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £54.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00Buy now
  • Pharmacy Registration Assessment Questions 3

    Pharmacy Registration Assessment Questions 3

    Pharmacy Registration Assessment Questions 3 is the third volume in a series that follows on from the previous, highly popular Pharmacy Registration Assessment Questions 2. It features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own.

    £35.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.